On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

On Tuesday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.02 or -2.67% from the prior close of $0.75. The stock opened at $0.75 and touched a low of ...

Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a ...

Monday announced safety and efficacy update for the Phase 1/2 OCU400 clinical trial for the treatment of early ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

Shares of Ocugen Inc. OCGN shed 5.16% to $0.83 Wednesday, on what proved to be an all-around positive trading session for the ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...